APO Research
Talk to an analyst

APO RESEARCH · REPORT

Influenzavirus B Infection Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Influenzavirus B Infection Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025195 pages

Choose your research edition.

Industry ResearchInfluenzavirus B Infection Drug Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Influenzavirus B Infection Drug Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Influenzavirus B Infection Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Influenzavirus B Infection Drug Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Influenzavirus B Infection Drug Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

The global Influenzavirus B Infection Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Influenzavirus B Infection Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Influenzavirus B Infection Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Influenzavirus B Infection Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Influenzavirus B Infection Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Influenzavirus B Infection Drug include Sanofi, AbbVie Inc, Vectura Group Plc, Vaxart Inc, TSRL Inc, SK Chemicals Co Ltd, Shionogi & Co Ltd, Sanofi Pasteur SA and Romark Laboratories LC, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Influenzavirus B Infection Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Influenzavirus B Infection Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Influenzavirus B Infection Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Influenzavirus B Infection Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Influenzavirus B Infection Drug Segment by Company

Sanofi

AbbVie Inc

Vectura Group Plc

Vaxart Inc

TSRL Inc

SK Chemicals Co Ltd

Shionogi & Co Ltd

Sanofi Pasteur SA

Romark Laboratories LC

Park Active Molecules

Novavax Inc

Mucosis BV

MedImmune LLC

Medicago Inc

Kineta Inc

Inovio Pharmaceuticals Inc

Green Cross Corp

GlaxoSmithKline Plc

Fujifilm Holdings Corporation

Daiichi Sankyo Company Ltd

ContraFect Corp

Cadila Healthcare Ltd

BioCryst Pharmaceuticals Inc

Aphios Corp

Amarillo Biosciences Inc

Altravax Inc

Adimmune Corp

Influenzavirus B Infection Drug Segment by Type

KIN-1400

GC-3106A

CF-403

APP-309

Others

Influenzavirus B Infection Drug Segment by Application

Clinic

Hospital

Others

Influenzavirus B Infection Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenzavirus B Infection Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Influenzavirus B Infection Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenzavirus B Infection Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Influenzavirus B Infection Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Influenzavirus B Infection Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Influenzavirus B Infection Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Influenzavirus B Infection Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Influenzavirus B Infection Drug Industry Trends Table 2. Influenzavirus B Infection Drug Industry Drivers Table 3. Influenzavirus B Infection Drug Industry Opportunities and Challenges Table 4. Influenzavirus B Infection Drug Industry Restraints Table 5. Global Influenzavirus B Infection Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Influenzavirus B Infection Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Influenzavirus B Infection Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Influenzavirus B Infection Drug Sales Market Share by Manufacturers Table 9. Global Influenzavirus B Infection Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Influenzavirus B Infection Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Influenzavirus B Infection Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Influenzavirus B Infection Drug Manufacturers, Product Type & Application Table 13. Global Influenzavirus B Infection Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Influenzavirus B Infection Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of KIN-1400 Table 17. Major Manufacturers of GC-3106A Table 18. Major Manufacturers of CF-403 Table 19. Major Manufacturers of APP-309 Table 20. Major Manufacturers of Others Table 21. Global Influenzavirus B Infection Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Influenzavirus B Infection Drug Sales by Type (2021-2026) & (K Units) Table 23. Global Influenzavirus B Infection Drug Sales by Type (2027-2032) & (K Units) Table 24. Global Influenzavirus B Infection Drug Sales Market Share by Type (2021-2026) Table 25. Global Influenzavirus B Infection Drug Sales Market Share by Type (2027-2032) Table 26. Global Influenzavirus B Infection Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Influenzavirus B Infection Drug Revenue by Type (2021-2026) & (K Units) Table 28. Global Influenzavirus B Infection Drug Revenue by Type (2027-2032) & (K Units) Table 29. Global Influenzavirus B Infection Drug Revenue Market Share by Type (2021-2026) Table 30. Global Influenzavirus B Infection Drug Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Clinic Table 32. Major Manufacturers of Hospital Table 33. Major Manufacturers of Others Table 34. Global Influenzavirus B Infection Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Influenzavirus B Infection Drug Sales by Application (2021-2026) & (K Units) Table 36. Global Influenzavirus B Infection Drug Sales by Application (2027-2032) & (K Units) Table 37. Global Influenzavirus B Infection Drug Sales Market Share by Application (2021-2026) Table 38. Global Influenzavirus B Infection Drug Sales Market Share by Application (2027-2032) Table 39. Global Influenzavirus B Infection Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Influenzavirus B Infection Drug Revenue by Application (2021-2026) & (K Units) Table 41. Global Influenzavirus B Infection Drug Revenue by Application (2027-2032) & (K Units) Table 42. Global Influenzavirus B Infection Drug Revenue Market Share by Application (2021-2026) Table 43. Global Influenzavirus B Infection Drug Revenue Market Share by Application (2027-2032) Table 44. Global Influenzavirus B Infection Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Influenzavirus B Infection Drug Sales by Region (2021-2026) & (K Units) Table 46. Global Influenzavirus B Infection Drug Sales Market Share by Region (2021-2026) Table 47. Global Influenzavirus B Infection Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Influenzavirus B Infection Drug Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Influenzavirus B Infection Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Influenzavirus B Infection Drug Sales by Country (2021-2026) & (K Units) Table 51. North America Influenzavirus B Infection Drug Sales by Country (2027-2032) & (K Units) Table 52. Europe Influenzavirus B Infection Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Influenzavirus B Infection Drug Sales by Country (2021-2026) & (K Units) Table 54. Europe Influenzavirus B Infection Drug Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Influenzavirus B Infection Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Influenzavirus B Infection Drug Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Influenzavirus B Infection Drug Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Influenzavirus B Infection Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Influenzavirus B Infection Drug Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Influenzavirus B Infection Drug Sales by Country (2027-2032) & (K Units) Table 61. Global Influenzavirus B Infection Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Influenzavirus B Infection Drug Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Influenzavirus B Infection Drug Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Influenzavirus B Infection Drug Revenue Market Share by Region (2021-2026) Table 65. Global Influenzavirus B Infection Drug Revenue Market Share by Region (2027-2032) Table 66. Sanofi Company Information Table 67. Sanofi Business Overview Table 68. Sanofi Influenzavirus B Infection Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Sanofi Influenzavirus B Infection Drug Product Portfolio Table 70. Sanofi Recent Development Table 71. AbbVie Inc Company Information Table 72. AbbVie Inc Business Overview Table 73. AbbVie Inc Influenzavirus B Infection Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. AbbVie Inc Influenzavirus B Infection Drug Product Portfolio Table 75. AbbVie Inc Recent Development Table 76. Vectura Group Plc Company Information Table 77. Vectura Group Plc Business Overview Table 78. Vectura Group Plc Influenzavirus B Infection Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Vectura Group Plc Influenzavirus B Infection Drug Product Portfolio Table 80. Vectura Group Plc Recent Development Table 81. Vaxart Inc Company Information Table 82. Vaxart Inc Business Overview Table 83. Vaxart Inc Influenzavirus B Infection Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Vaxart Inc Influenzavirus B Infection Drug Product Portfolio Table 85. Vaxart Inc Recent Development Table 86. TSRL Inc Company Information Table 87. TSRL Inc Business Overview Table 88. TSRL Inc Influenzavirus B Infection Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. TSRL Inc Influenzavirus B Infection Drug Product Portfolio Table 90. TSRL Inc Recent Development Table 91. SK Chemicals Co Ltd Company Information Table 92. SK Chemicals Co Ltd Business Overview Table 93. SK Chemicals Co Ltd Influenzavirus B Infection Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. SK Chemicals Co Ltd Influenzavirus B Infection Drug Product Portfolio Table 95. SK Chemicals Co Ltd Recent Development Table 96. Shionogi & Co Ltd Company Information Table 97. Shionogi & Co Ltd Business Overview Table 98. Shionogi & Co Ltd Influenzavirus B Infection Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Shionogi & Co Ltd Influenzavirus B Infection Drug Product Portfolio Table 100. Shionogi & Co Ltd Recent Development Table 101. Sanofi Pasteur SA Company Information Table 102. Sanofi Pasteur SA Business Overview Table 103. Sanofi Pasteur SA Influenzavirus B Infection Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Sanofi Pasteur SA Influenzavirus B Infection Drug Product Portfolio Table 105. Sanofi Pasteur SA Recent Development Table 106. Romark Laboratories LC Company Information Table 107. Romark Laboratories LC Business Overview Table 108. Romark Laboratories LC Influenzavirus B Infection Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Romark Laboratories LC Influenzavirus B Infection Drug Product Portfolio Table 110. Romark Laboratories LC Recent Development Table 111. Park Active Molecules Company Information Table 112. Park Active Molecules Business Overview Table 113. Park Active Molecules Influenzavirus B Infection Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Park Active Molecules Influenzavirus B Infection Drug Product Portfolio Table 115. Park Active Molecules Recent Development Table 116. Novavax Inc Company Information Table 117. Novavax Inc Business Overview Table 118. Novavax Inc Influenzavirus B Infection Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Novavax Inc Influenzavirus B Infection Drug Product Portfolio Table 120. Novavax Inc Recent Development Table 121. Mucosis BV Company Information Table 122. Mucosis BV Business Overview Table 123. Mucosis BV Influenzavirus B Infection Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Mucosis BV Influenzavirus B Infection Drug Product Portfolio Table 125. Mucosis BV Recent Development Table 126. MedImmune LLC Company Information Table 127. MedImmune LLC Business Overview Table 128. MedImmune LLC Influenzavirus B Infection Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. MedImmune LLC Influenzavirus B Infection Drug Product Portfolio Table 130. MedImmune LLC Recent Development Table 131. Medicago Inc Company Information Table 132. Medicago Inc Business Overview Table 133. Medicago Inc Influenzavirus B Infection Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. Medicago Inc Influenzavirus B Infection Drug Product Portfolio Table 135. Medicago Inc Recent Development Table 136. Kineta Inc Company Information Table 137. Kineta Inc Business Overview Table 138. Kineta Inc Influenzavirus B Infection Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 139. Kineta Inc Influenzavirus B Infection Drug Product Portfolio Table 140. Kineta Inc Recent Development Table 141. Inovio Pharmaceuticals Inc Company Information Table 142. Inovio Pharmaceuticals Inc Business Overview Table 143. Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 144. Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Product Portfolio Table 145. Inovio Pharmaceuticals Inc Recent Development Table 146. Green Cross Corp Company Information Table 147. Green Cross Corp Business Overview Table 148. Green Cross Corp Influenzavirus B Infection Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 149. Green Cross Corp Influenzavirus B Infection Drug Product Portfolio Table 150. Green Cross Corp Recent Development Table 151. GlaxoSmithKline Plc Company Information Table 152. GlaxoSmithKline Plc Business Overview Table 153. GlaxoSmithKline Plc Influenzavirus B Infection Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 154. GlaxoSmithKline Plc Influenzavirus B Infection Drug Product Portfolio Table 155. GlaxoSmithKline Plc Recent Development Table 156. Fujifilm Holdings Corporation Company Information Table 157. Fujifilm Holdings Corporation Business Overview Table 158. Fujifilm Holdings Corporation Influenzavirus B Infection Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 159. Fujifilm Holdings Corporation Influenzavirus B Infection Drug Product Portfolio Table 160. Fujifilm Holdings Corporation Recent Development Table 161. Daiichi Sankyo Company Ltd Company Information Table 162. Daiichi Sankyo Company Ltd Business Overview Table 163. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 164. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Product Portfolio Table 165. Daiichi Sankyo Company Ltd Recent Development Table 166. ContraFect Corp Company Information Table 167. ContraFect Corp Business Overview Table 168. ContraFect Corp Influenzavirus B Infection Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 169. ContraFect Corp Influenzavirus B Infection Drug Product Portfolio Table 170. ContraFect Corp Recent Development Table 171. Cadila Healthcare Ltd Company Information Table 172. Cadila Healthcare Ltd Business Overview Table 173. Cadila Healthcare Ltd Influenzavirus B Infection Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 174. Cadila Healthcare Ltd Influenzavirus B Infection Drug Product Portfolio Table 175. Cadila Healthcare Ltd Recent Development Table 176. BioCryst Pharmaceuticals Inc Company Information Table 177. BioCryst Pharmaceuticals Inc Business Overview Table 178. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 179. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Product Portfolio Table 180. BioCryst Pharmaceuticals Inc Recent Development Table 181. Aphios Corp Company Information Table 182. Aphios Corp Business Overview Table 183. Aphios Corp Influenzavirus B Infection Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 184. Aphios Corp Influenzavirus B Infection Drug Product Portfolio Table 185. Aphios Corp Recent Development Table 186. Amarillo Biosciences Inc Company Information Table 187. Amarillo Biosciences Inc Business Overview Table 188. Amarillo Biosciences Inc Influenzavirus B Infection Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 189. Amarillo Biosciences Inc Influenzavirus B Infection Drug Product Portfolio Table 190. Amarillo Biosciences Inc Recent Development Table 191. Altravax Inc Company Information Table 192. Altravax Inc Business Overview Table 193. Altravax Inc Influenzavirus B Infection Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 194. Altravax Inc Influenzavirus B Infection Drug Product Portfolio Table 195. Altravax Inc Recent Development Table 196. Adimmune Corp Company Information Table 197. Adimmune Corp Business Overview Table 198. Adimmune Corp Influenzavirus B Infection Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 199. Adimmune Corp Influenzavirus B Infection Drug Product Portfolio Table 200. Adimmune Corp Recent Development Table 201. Key Raw Materials Table 202. Raw Materials Key Suppliers Table 203. Influenzavirus B Infection Drug Distributors List Table 204. Influenzavirus B Infection Drug Customers List Table 205. Research Programs/Design for This Report Table 206. Authors List of This Report Table 207. Secondary Sources Table 208. Primary Sources List of Figures Figure 1. Influenzavirus B Infection Drug Product Image Figure 2. Global Influenzavirus B Infection Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Influenzavirus B Infection Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Influenzavirus B Infection Drug Sales (2021-2032) & (K Units) Figure 5. Global Influenzavirus B Infection Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Influenzavirus B Infection Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. KIN-1400 Image Figure 9. GC-3106A Image Figure 10. CF-403 Image Figure 11. APP-309 Image Figure 12. Others Image Figure 13. Global Influenzavirus B Infection Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Influenzavirus B Infection Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Influenzavirus B Infection Drug Sales Market Share by Type (2021-2032) Figure 16. Global Influenzavirus B Infection Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Influenzavirus B Infection Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Influenzavirus B Infection Drug Revenue Market Share by Type (2021-2032) Figure 19. Clinic Image Figure 20. Hospital Image Figure 21. Others Image Figure 22. Global Influenzavirus B Infection Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Influenzavirus B Infection Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Influenzavirus B Infection Drug Sales Market Share by Application (2021-2032) Figure 25. Global Influenzavirus B Infection Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Influenzavirus B Infection Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Influenzavirus B Infection Drug Revenue Market Share by Application (2021-2032) Figure 28. North America Influenzavirus B Infection Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Influenzavirus B Infection Drug Sales Market Share by Country (2021-2032) Figure 30. U.S. Influenzavirus B Infection Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Influenzavirus B Infection Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Influenzavirus B Infection Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Influenzavirus B Infection Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Influenzavirus B Infection Drug Sales Market Share by Country (2021-2032) Figure 35. Germany Influenzavirus B Infection Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Influenzavirus B Infection Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Influenzavirus B Infection Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Influenzavirus B Infection Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Influenzavirus B Infection Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Influenzavirus B Infection Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Influenzavirus B Infection Drug Sales Market Share by Country (2021-2032) Figure 42. China Influenzavirus B Infection Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Influenzavirus B Infection Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Influenzavirus B Infection Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Influenzavirus B Infection Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Influenzavirus B Infection Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Influenzavirus B Infection Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Influenzavirus B Infection Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Influenzavirus B Infection Drug Sales Market Share by Country (2021-2032) Figure 50. Brazil Influenzavirus B Infection Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Influenzavirus B Infection Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Influenzavirus B Infection Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Influenzavirus B Infection Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Influenzavirus B Infection Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Influenzavirus B Infection Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Influenzavirus B Infection Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Influenzavirus B Infection Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Influenzavirus B Infection Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Influenzavirus B Infection Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Influenzavirus B Infection Drug Revenue (2021-2032) & (US$ Million) Figure 61. North America Influenzavirus B Infection Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Influenzavirus B Infection Drug Revenue (2021-2032) & (US$ Million) Figure 63. Europe Influenzavirus B Infection Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Influenzavirus B Infection Drug Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Influenzavirus B Infection Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Influenzavirus B Infection Drug Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Influenzavirus B Infection Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Influenzavirus B Infection Drug Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Influenzavirus B Infection Drug Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • KIN-1400
  • GC-3106A
  • CF-403
  • APP-309
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Sanofi
  • AbbVie Inc
  • Vectura Group Plc
  • Vaxart Inc
  • TSRL Inc
  • SK Chemicals Co Ltd
  • Shionogi & Co Ltd
  • Sanofi Pasteur SA
  • Romark Laboratories LC
  • Park Active Molecules
  • Novavax Inc
  • Mucosis BV
  • MedImmune LLC
  • Medicago Inc
  • Kineta Inc
  • Inovio Pharmaceuticals Inc
  • Green Cross Corp
  • GlaxoSmithKline Plc
  • Fujifilm Holdings Corporation
  • Daiichi Sankyo Company Ltd
  • ContraFect Corp
  • Cadila Healthcare Ltd
  • BioCryst Pharmaceuticals Inc
  • Aphios Corp
  • Amarillo Biosciences Inc
  • Altravax Inc
  • Adimmune Corp

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Influenzavirus B Infection Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Influenzavirus B Infection Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Influenzavirus B Infection Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Influenzavirus B Infection Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Influenzavirus B Infection Drug Market Dynamics
  1. 2.1 Influenzavirus B Infection Drug Industry Trends
  2. 2.2 Influenzavirus B Infection Drug Industry Drivers
  3. 2.3 Influenzavirus B Infection Drug Industry Opportunities and Challenges
  4. 2.4 Influenzavirus B Infection Drug Industry Restraints
3 Influenzavirus B Infection Drug Market by Manufacturers
  1. 3.1 Global Influenzavirus B Infection Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Influenzavirus B Infection Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Influenzavirus B Infection Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Influenzavirus B Infection Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Influenzavirus B Infection Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Influenzavirus B Infection Drug Manufacturers, Product Type & Application
  7. 3.7 Global Influenzavirus B Infection Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Influenzavirus B Infection Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Influenzavirus B Infection Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Influenzavirus B Infection Drug Tier 1, Tier 2, and Tier 3
4 Influenzavirus B Infection Drug Market by Type
  1. 4.1 Influenzavirus B Infection Drug Type Introduction
  2. 4.1.1 KIN-1400
  3. 4.1.2 GC-3106A
  4. 4.1.3 CF-403
  5. 4.1.4 APP-309
  6. 4.1.5 Others
  7. 4.2 Global Influenzavirus B Infection Drug Sales by Type
  8. 4.2.1 Global Influenzavirus B Infection Drug Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Influenzavirus B Infection Drug Sales by Type (2021-2032)
  10. 4.2.3 Global Influenzavirus B Infection Drug Sales Market Share by Type (2021-2032)
  11. 4.3 Global Influenzavirus B Infection Drug Revenue by Type
  12. 4.3.1 Global Influenzavirus B Infection Drug Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Influenzavirus B Infection Drug Revenue by Type (2021-2032)
  14. 4.3.3 Global Influenzavirus B Infection Drug Revenue Market Share by Type (2021-2032)
5 Influenzavirus B Infection Drug Market by Application
  1. 5.1 Influenzavirus B Infection Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Influenzavirus B Infection Drug Sales by Application
  6. 5.2.1 Global Influenzavirus B Infection Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Influenzavirus B Infection Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Influenzavirus B Infection Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Influenzavirus B Infection Drug Revenue by Application
  10. 5.3.1 Global Influenzavirus B Infection Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Influenzavirus B Infection Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Influenzavirus B Infection Drug Revenue Market Share by Application (2021-2032)
6 Global Influenzavirus B Infection Drug Sales by Region
  1. 6.1 Global Influenzavirus B Infection Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Influenzavirus B Infection Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Influenzavirus B Infection Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Influenzavirus B Infection Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Influenzavirus B Infection Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Influenzavirus B Infection Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Influenzavirus B Infection Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Influenzavirus B Infection Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Influenzavirus B Infection Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Influenzavirus B Infection Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Influenzavirus B Infection Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Influenzavirus B Infection Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Influenzavirus B Infection Drug Revenue by Region
  1. 7.1 Global Influenzavirus B Infection Drug Revenue by Region
  2. 7.1.1 Global Influenzavirus B Infection Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Influenzavirus B Infection Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Influenzavirus B Infection Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Influenzavirus B Infection Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Influenzavirus B Infection Drug Revenue (2021-2032)
  8. 7.2.2 North America Influenzavirus B Infection Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Influenzavirus B Infection Drug Revenue (2021-2032)
  11. 7.3.2 Europe Influenzavirus B Infection Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Influenzavirus B Infection Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Influenzavirus B Infection Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Influenzavirus B Infection Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Influenzavirus B Infection Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Influenzavirus B Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Influenzavirus B Infection Drug Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 AbbVie Inc
  8. 8.2.1 AbbVie Inc Company Information
  9. 8.2.2 AbbVie Inc Business Overview
  10. 8.2.3 AbbVie Inc Influenzavirus B Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 AbbVie Inc Influenzavirus B Infection Drug Product Portfolio
  12. 8.2.5 AbbVie Inc Recent Developments
  13. 8.3 Vectura Group Plc
  14. 8.3.1 Vectura Group Plc Company Information
  15. 8.3.2 Vectura Group Plc Business Overview
  16. 8.3.3 Vectura Group Plc Influenzavirus B Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Vectura Group Plc Influenzavirus B Infection Drug Product Portfolio
  18. 8.3.5 Vectura Group Plc Recent Developments
  19. 8.4 Vaxart Inc
  20. 8.4.1 Vaxart Inc Company Information
  21. 8.4.2 Vaxart Inc Business Overview
  22. 8.4.3 Vaxart Inc Influenzavirus B Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Vaxart Inc Influenzavirus B Infection Drug Product Portfolio
  24. 8.4.5 Vaxart Inc Recent Developments
  25. 8.5 TSRL Inc
  26. 8.5.1 TSRL Inc Company Information
  27. 8.5.2 TSRL Inc Business Overview
  28. 8.5.3 TSRL Inc Influenzavirus B Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 TSRL Inc Influenzavirus B Infection Drug Product Portfolio
  30. 8.5.5 TSRL Inc Recent Developments
  31. 8.6 SK Chemicals Co Ltd
  32. 8.6.1 SK Chemicals Co Ltd Company Information
  33. 8.6.2 SK Chemicals Co Ltd Business Overview
  34. 8.6.3 SK Chemicals Co Ltd Influenzavirus B Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 SK Chemicals Co Ltd Influenzavirus B Infection Drug Product Portfolio
  36. 8.6.5 SK Chemicals Co Ltd Recent Developments
  37. 8.7 Shionogi & Co Ltd
  38. 8.7.1 Shionogi & Co Ltd Company Information
  39. 8.7.2 Shionogi & Co Ltd Business Overview
  40. 8.7.3 Shionogi & Co Ltd Influenzavirus B Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Shionogi & Co Ltd Influenzavirus B Infection Drug Product Portfolio
  42. 8.7.5 Shionogi & Co Ltd Recent Developments
  43. 8.8 Sanofi Pasteur SA
  44. 8.8.1 Sanofi Pasteur SA Company Information
  45. 8.8.2 Sanofi Pasteur SA Business Overview
  46. 8.8.3 Sanofi Pasteur SA Influenzavirus B Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sanofi Pasteur SA Influenzavirus B Infection Drug Product Portfolio
  48. 8.8.5 Sanofi Pasteur SA Recent Developments
  49. 8.9 Romark Laboratories LC
  50. 8.9.1 Romark Laboratories LC Company Information
  51. 8.9.2 Romark Laboratories LC Business Overview
  52. 8.9.3 Romark Laboratories LC Influenzavirus B Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Romark Laboratories LC Influenzavirus B Infection Drug Product Portfolio
  54. 8.9.5 Romark Laboratories LC Recent Developments
  55. 8.10 Park Active Molecules
  56. 8.10.1 Park Active Molecules Company Information
  57. 8.10.2 Park Active Molecules Business Overview
  58. 8.10.3 Park Active Molecules Influenzavirus B Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Park Active Molecules Influenzavirus B Infection Drug Product Portfolio
  60. 8.10.5 Park Active Molecules Recent Developments
  61. 8.11 Novavax Inc
  62. 8.11.1 Novavax Inc Company Information
  63. 8.11.2 Novavax Inc Business Overview
  64. 8.11.3 Novavax Inc Influenzavirus B Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Novavax Inc Influenzavirus B Infection Drug Product Portfolio
  66. 8.11.5 Novavax Inc Recent Developments
  67. 8.12 Mucosis BV
  68. 8.12.1 Mucosis BV Company Information
  69. 8.12.2 Mucosis BV Business Overview
  70. 8.12.3 Mucosis BV Influenzavirus B Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Mucosis BV Influenzavirus B Infection Drug Product Portfolio
  72. 8.12.5 Mucosis BV Recent Developments
  73. 8.13 MedImmune LLC
  74. 8.13.1 MedImmune LLC Company Information
  75. 8.13.2 MedImmune LLC Business Overview
  76. 8.13.3 MedImmune LLC Influenzavirus B Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 MedImmune LLC Influenzavirus B Infection Drug Product Portfolio
  78. 8.13.5 MedImmune LLC Recent Developments
  79. 8.14 Medicago Inc
  80. 8.14.1 Medicago Inc Company Information
  81. 8.14.2 Medicago Inc Business Overview
  82. 8.14.3 Medicago Inc Influenzavirus B Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Medicago Inc Influenzavirus B Infection Drug Product Portfolio
  84. 8.14.5 Medicago Inc Recent Developments
  85. 8.15 Kineta Inc
  86. 8.15.1 Kineta Inc Company Information
  87. 8.15.2 Kineta Inc Business Overview
  88. 8.15.3 Kineta Inc Influenzavirus B Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Kineta Inc Influenzavirus B Infection Drug Product Portfolio
  90. 8.15.5 Kineta Inc Recent Developments
  91. 8.16 Inovio Pharmaceuticals Inc
  92. 8.16.1 Inovio Pharmaceuticals Inc Company Information
  93. 8.16.2 Inovio Pharmaceuticals Inc Business Overview
  94. 8.16.3 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Product Portfolio
  96. 8.16.5 Inovio Pharmaceuticals Inc Recent Developments
  97. 8.17 Green Cross Corp
  98. 8.17.1 Green Cross Corp Company Information
  99. 8.17.2 Green Cross Corp Business Overview
  100. 8.17.3 Green Cross Corp Influenzavirus B Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Green Cross Corp Influenzavirus B Infection Drug Product Portfolio
  102. 8.17.5 Green Cross Corp Recent Developments
  103. 8.18 GlaxoSmithKline Plc
  104. 8.18.1 GlaxoSmithKline Plc Company Information
  105. 8.18.2 GlaxoSmithKline Plc Business Overview
  106. 8.18.3 GlaxoSmithKline Plc Influenzavirus B Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 GlaxoSmithKline Plc Influenzavirus B Infection Drug Product Portfolio
  108. 8.18.5 GlaxoSmithKline Plc Recent Developments
  109. 8.19 Fujifilm Holdings Corporation
  110. 8.19.1 Fujifilm Holdings Corporation Company Information
  111. 8.19.2 Fujifilm Holdings Corporation Business Overview
  112. 8.19.3 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Product Portfolio
  114. 8.19.5 Fujifilm Holdings Corporation Recent Developments
  115. 8.20 Daiichi Sankyo Company Ltd
  116. 8.20.1 Daiichi Sankyo Company Ltd Company Information
  117. 8.20.2 Daiichi Sankyo Company Ltd Business Overview
  118. 8.20.3 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Product Portfolio
  120. 8.20.5 Daiichi Sankyo Company Ltd Recent Developments
  121. 8.21 ContraFect Corp
  122. 8.21.1 ContraFect Corp Company Information
  123. 8.21.2 ContraFect Corp Business Overview
  124. 8.21.3 ContraFect Corp Influenzavirus B Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 ContraFect Corp Influenzavirus B Infection Drug Product Portfolio
  126. 8.21.5 ContraFect Corp Recent Developments
  127. 8.22 Cadila Healthcare Ltd
  128. 8.22.1 Cadila Healthcare Ltd Company Information
  129. 8.22.2 Cadila Healthcare Ltd Business Overview
  130. 8.22.3 Cadila Healthcare Ltd Influenzavirus B Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Cadila Healthcare Ltd Influenzavirus B Infection Drug Product Portfolio
  132. 8.22.5 Cadila Healthcare Ltd Recent Developments
  133. 8.23 BioCryst Pharmaceuticals Inc
  134. 8.23.1 BioCryst Pharmaceuticals Inc Company Information
  135. 8.23.2 BioCryst Pharmaceuticals Inc Business Overview
  136. 8.23.3 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  137. 8.23.4 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Product Portfolio
  138. 8.23.5 BioCryst Pharmaceuticals Inc Recent Developments
  139. 8.24 Aphios Corp
  140. 8.24.1 Aphios Corp Company Information
  141. 8.24.2 Aphios Corp Business Overview
  142. 8.24.3 Aphios Corp Influenzavirus B Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Aphios Corp Influenzavirus B Infection Drug Product Portfolio
  144. 8.24.5 Aphios Corp Recent Developments
  145. 8.25 Amarillo Biosciences Inc
  146. 8.25.1 Amarillo Biosciences Inc Company Information
  147. 8.25.2 Amarillo Biosciences Inc Business Overview
  148. 8.25.3 Amarillo Biosciences Inc Influenzavirus B Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  149. 8.25.4 Amarillo Biosciences Inc Influenzavirus B Infection Drug Product Portfolio
  150. 8.25.5 Amarillo Biosciences Inc Recent Developments
  151. 8.26 Altravax Inc
  152. 8.26.1 Altravax Inc Company Information
  153. 8.26.2 Altravax Inc Business Overview
  154. 8.26.3 Altravax Inc Influenzavirus B Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  155. 8.26.4 Altravax Inc Influenzavirus B Infection Drug Product Portfolio
  156. 8.26.5 Altravax Inc Recent Developments
  157. 8.27 Adimmune Corp
  158. 8.27.1 Adimmune Corp Company Information
  159. 8.27.2 Adimmune Corp Business Overview
  160. 8.27.3 Adimmune Corp Influenzavirus B Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  161. 8.27.4 Adimmune Corp Influenzavirus B Infection Drug Product Portfolio
  162. 8.27.5 Adimmune Corp Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Influenzavirus B Infection Drug Value Chain Analysis
  2. 9.1.1 Influenzavirus B Infection Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Influenzavirus B Infection Drug Production Mode & Process
  6. 9.2 Influenzavirus B Infection Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Influenzavirus B Infection Drug Distributors
  9. 9.2.3 Influenzavirus B Infection Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst